Histone deacetylase (HDAC) is a promising target for cancer treatment. HDAC inhibitors consist of three pharmacophoric features: an aromatic cap group, zinc binding group (ZBG), and a linker chain connecting cap group to ZBG. Herein, we report on (i) substituted isatin moiety as the cap group that recognizes the surface of active enzyme pocket and (ii) thiosemicarbazide moiety incorporated as linker group responsible for connecting the cap group to ZBG (hydroxamic acid). The synthesized compounds were evaluated for their antiproliferative activity and HDAC enzyme inhibition. The binding mode analysis of proposed compounds was evaluated by docking studies. Several analogs were found to inhibit HDAC and cellular proliferation of Hela cervical cancer cells, with GI50 values in the micromolar range. One compound (Vd) was found to have greater in vitro antiproliferative activity in comparison to other compounds.
组蛋白
去乙酰化酶(H
DAC)是癌症治疗的潜在靶点。H
DAC抑制剂由三种药效团特征组成:芳香的帽状基团、
锌结合基团(ZBG)以及连接帽状基团与ZBG的链接链。本文报道了(i)取代的异
吲哚酮部分作为帽状基团,识别活性酶口袋表面,以及(ii)结合为链接基团负责连接帽状基团与ZBG(羟
肟酸)的酰
肼部分。所合成的化合物进行了抗增殖活性和H
DAC酶抑制活性的评估。通过对接研究评估了所提出化合物的结合模式。发现多个类似物能够抑制H
DAC及宫颈癌Hela细胞的增殖,其GI50值在微摩尔范围内。其中一个化合物(Vd)相较于其他化合物显示出更强的体外抗增殖活性。